Comparison

AZD6482 European Partner

Item no. S1462-10
Manufacturer Selleckchem
CASRN 1173900-33-8
Amount 10 mg
Quantity options 10 mg 1 g 10 g 5 mg 50 mg 5 g
Category
Type Inhibitors
Specific against other
Smiles CC1=CN2C(=O)C=C(N=C2C(=C1)C(C)NC3=CC=CC=C3C(=O)O)N4CCOCC4
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias KIN-193
Similar products AZD6482
Available
Manufacturer - Targets
PI3K
Storage Conditions
2 years -80 in solvent
Molecular Weight
408, 45
Cell lines
Human platelet pellet
Clinical Trials
Investigations of AZD6482 in two Phase I clinical trials for antiplatelet effect have been completed.
Concentrations
0–60 nM, dissolved in DMSO
IC50
21 nM, 21 nM, 21 nM, 21 nM, 21 nM, 21 nM
In vitro
AZD6482 also inhibits PI3Kalpha, gamma, and delta, with IC50 of 80 nM to 1.4 uM, which are significantly lower than its (+)-enantiomer (S-form). AZD6482 is an antiplatelet agent, it blocks platelet activation adhesion/aggregation and promotes platelet disaggregation in assay of washed platelet aggregation (WPA), with an IC50 value of 6 nM. Furthermore, by targeting PI3Kbeta, AZD6482 specifically inhibits thrombosis without interfering with normal haemostasis. Therefore, AZD6482 is used as an anti-thrombotic drug for the prophylaxis of thrombotic disorders. [1]
Incubation Time
5 min
Kinase Assay
Assay of PI3K enzyme inhibition, The inhibition of PI3Kbeta, PI3Kalpha, PI3Kgamma, and PI3Kdelta is evaluated in an AlphaScreen based enzyme activity assay using human recombinant enzymes. The assay measures PI3K-mediated conversion of PIP2 to PIP3. Biotinylated PIP3, a GST-tagged pleckstrin homology (PH) domain and the two AlphaScreen beads form a complex that elicits a signal upon laser excitation at 680 nm. The PIP3 formed in the enzyme reaction competes with the biotinylated PIP3 for binding to the PH domain thus reducing the signal with increasing enzyme product., The AZD6482 is dissolved in DMSO and added to 384 well plates. PBKbeta, PBKalpha, PBKgamma, or PBKdelta is added in a Tris buffer (50 mM Tris pH 7.6, 0.05% CHAPS, 5 mM DTT, and 24 mM MgCl2) and allowed to preincubate with AZD6482 for 20 minutes prior to the addition of substrate solution containing PIP2 and ATP. The enzyme reaction is stopped after 20 minutes by addition of stop solution containing EDTA and biotin-PIP3, followed by addition of detection solution containing GST-grpl PH and AlphaScreen beads. Plates are left for a minimum of 5 hours in the dark prior to analysis. The final concentration of DMSO, ATP and PIP2 in the assay are, 0.8%, 4 uM, and 40 uM, respectively. IC50 values are calculated according to the equation, y = {a+[(b-a)/(l+(x/IC50)s)]}, where y = % inhibition, a = 0%, b = 100%, s = the slope of the concentration-response curve, x = AZD6482 concentration.
Method
For assay of washed platelet aggregation (WPA), the platelet pellets are isolated from human blood and re-suspended to 2 x 1015/L in Tyrodes buffer (TB) containing 1 uM hirudin and 0.02 U/mL apyrase. Then, the platelet suspension is left to rest at room temperature for 30 min. Just prior to time for assay, CaCl2 is added to a final concentration of 2 mM. AZD6482, dissolved in DMSO, is added to a 96-well plate prior to the addition of the washed platelet suspension. The platelet suspension is preincubated with AZD6482 for 5 min. Light absorption at 650 nm is recorded before and after a 5 min plate shake and referred to as recording 0 (R0) and Rl. A mouse anti-human CD9 antibody is added (at a donor specific concentration) to each well prior to next 10 min plate shake and light absorption recording, R2. For data analysis, light absorbance in wells with TB are subtracted from all readings before percent aggregation is calculated according the formula: [(R1-R2)/R1] x 100 = % aggregation. Spontaneous aggregation or pro-aggregatory effect of the inhibitor is evaluated by the same formula, [(R0-Rl)/R0] x 100 = % aggregation. IC50 values are calculated according to the equation, y = {a+[(b-a)/(l+(x/IC50)s)]}, where y = % inhibition, a = 0%, b = 100%, s = the slope of the concentration-response curve, x = AZD6482 concentration.
Solubility (25C)
DMSO 82 mg/mL, Water <1 mg/mL, Ethanol 28 mg/mL
Information
AZD6482 (KIN-193) is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ in cell-free assays. Phase 1.
Chemical Name
(R)-2-(1-(7-methyl-2-morpholino-4-oxo-4H-pyrido[1, 2-a]pyrimidin-9-yl)ethylamino)benzoic acid

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 10 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?